GlassScriptPhysician profile
Tasnuva Amin
NPI 1497377923
$1,326.91
in general payments reported to CMS, 2019-2025
20 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $31.56 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $205.84 | 2025 | Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $154.17 | 2025 | Gvoke Hypopen, Recorlev |
| Astellas Pharma US INC | $125.00 | 2025 | Veozah |
| Corcept Therapeutics | $122.37 | 2025 | Korlym |
| Lilly USA, LLC | $96.34 | 2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $78.41 | 2025 | Freestyle Libre 3, Proclaim |
| Radius Health, INC. | $71.20 | 2025 | Tymlos |
| Amgen INC. | $65.51 | 2024-2025 | Tepezza |
| Sanofi-Aventis U.S. LLC | $59.38 | 2025 | |
| Recordati_rare_diseases_inc. | $56.98 | 2025 | Isturisa |
| Insulet Corporation | $53.08 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $47.04 | 2025 | |
| Alexion Pharmaceuticals, INC. | $36.94 | 2025 | Strensiq |
| Abbvie INC. | $33.48 | 2025 | |
| Madrigal Pharmaceuticals | $28.59 | 2025 | Rezdiffra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $23.02 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $19.19 | 2025 | Minimed 780g |
| Ionis Pharmaceuticals, INC. | $17.96 | 2025 | Tryngolza |
| Chiesi USA, INC. | $17.10 | 2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $15.31 | 2025 | Yorvipath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasnuva Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.